2021-07-08| Asia-PacificCOVID-19

Japan’s Shionogi to Provide 120 Million Doses of COVID-19 Vaccines Annually

by Kathy Huang
Share To

On July 7th, Japan’s drugmaker Shionogi announced that it will provide up to 120 million doses of COVID-19 vaccine annually, which is double its previous plan to supply 60 million doses in an announcement made on June 28th.

In the original plan, Shionogi said it would be able to provide vaccine doses for 30 million people at the rate of two shots per person a year, which is the same as those made by Pfizer. However, it has been difficult to conduct large-scale trials in Japan.

Unlike the mRNA vaccines, Shionogi found that its vaccines were effective even in a lower dosage. Therefore, it plans to expand the supply of vaccines. The appropriate dosage will be determined in the following clinical trials. If Shionogi can get Japan’s fast-track approval, it will start providing vaccine doses this year.


Progress of Clinical Trials

Shionogi produces recombinant protein-based COVID-19 vaccines. The company began its Phase 1/2 clinical trial involving around 200 volunteers in December last year, which is Japan’s second clinical trial for COVID-19 vaccines after AnGes’.

Shionogi will launch the Phase 3 clinical trial by the end of September. Also, it will expand the ongoing Phase 1/2 trial to determine the appropriate dosage of its vaccines.


Recent Development of Japan’s Indigenous COVID-19 Vaccines

AnGes’ DNA vaccine AG0302-COVID19 and AG0301-COVID19 have entered Phase 3 clinical trials with high expectations to bag Japan’s Emergency Use Authorization approval.

On March 22nd, Daiichi Sankyo launched Phase 1/2 clinical trials of its mRNA vaccine, DS-5670, enrolling 152 volunteers.

On the same day, KM Biologics also began Phase 1/2 clinical trials recruiting 210 people to evaluate the vaccine’s safety and the ability to trigger immune responses. The vaccine candidate uses killed coronavirus particles to activate an immune response.


Related Article: Japan’s Shionogi Grants US Company the Rights to Develop a Repurposed Allergic Rhinitis Drug as a COVID-19 Cure


© All rights reserved. Collaborate with us: [email protected]
Related Post
STLI Webinar Series 1: Experts Discuss Regulatory Trends in Regenerative Medicine
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
Assessment of Supply Chain Risk Key to Improving Medicine Access
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
Autoimmune Patients See Breakthrough Response to Allogeneic CD19-Targeted CAR-T Therapy
Scroll to Top